Search This Blog

Thursday, May 7, 2026

Xeris ups guidance with commercialization ramp

 

Xeris Biopharma beats Q1 2026 estimates with non-GAAP EPS $0.01 (+117% YoY), revenue $82.5M (+43% YoY), raises 2026 guidance

  • Company posts Q1 2026 profit with EPS $0.01 on $83.1M revenue, marking a return to net income
  • Raises 2026 revenue guidance to $380–$390M
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)